Deep dive into drug substance HCP patterns for comprehensive safety assessment in recombinant mAb formats.

Waldera-Lupa DM, Gehrke-Oltmanns A, Dehghani A, Morgenroth M, Betz AA, Falkenberg H, Flad T, Backofen U, Waerner T

DOI: 10.1002/btpr.88540
Published: 2026 Jul 7
Container: Biotechnology progress
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/btpr.88540,
  title = {Deep dive into drug substance HCP patterns for comprehensive safety assessment in recombinant mAb formats.},
  author = {Waldera-Lupa DM and Gehrke-Oltmanns A and Dehghani A and Morgenroth M and Betz AA and Falkenberg H and Flad T and Backofen U and Waerner T},
  year = {2026},
  journal = {Biotechnology progress},
  doi = {10.1002/btpr.88540},
  url = {https://doi.org/10.1002/btpr.88540}
}

RIS

TY  - JOUR
TI  - Deep dive into drug substance HCP patterns for comprehensive safety assessment in recombinant mAb formats.
AU  - Waldera-Lupa DM
AU  - Gehrke-Oltmanns A
AU  - Dehghani A
AU  - Morgenroth M
AU  - Betz AA
AU  - Falkenberg H
AU  - Flad T
AU  - Backofen U
AU  - Waerner T
PY  - 2026
JO  - Biotechnology progress
DO  - 10.1002/btpr.88540
UR  - https://doi.org/10.1002/btpr.88540
ER  -

APA

DM, W., A, G., A, D., M, M., AA, B., H, F., T, F., U, B., & T, W. (2026). Deep dive into drug substance HCP patterns for comprehensive safety assessment in recombinant mAb formats.. Biotechnology progress. https://doi.org/10.1002/btpr.88540

Source records

pubmed · retrieved 2026-09-25T08:23:21.136Z